That's quite pleasing. A Patent for treatment of BML and...

That's quite pleasing.

A Patent for treatment of BML and concurrent OA in the knee in Australia with PPS.

On top of having supply exclusivity for all major pharma markets and regions (for 25 years after registration) of the only PPS approved for human use (and which has the only DMF with the FDA), as well as the 3 years of regulatory exclusivity via the 505b2 pathway in the USA upon registration, these patents adds an extra layer of IP protection to an already pretty bulletproof position.

Hopefully this assists in acquiring the same patent in the US....not that (as Morgans were recently schooled) this is the be all and end all. No PPS-biosimilar competitor is going to get a look in for a decade anyway. By that stage, all being well, PAR and whoever is lucky enough to partner with PAR, will have a dominant market share position to cling to and build on with other indications/repurposed molecules.

I mean, that's the plan anyway. Could do with some cash to make it happen etc.